FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

NEXT STORY
Aptose Biosciences Establishes New At-The-Market Facility
PREV STORY
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Study with Abiomed’s Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery

DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider ...

author_avatar
NASDAQ Market News

Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium

author_avatar
NASDAQ Market News

ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium

Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase ...

author_avatar
NASDAQ Market News